Media

Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
January 2, 2020

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

November 5, 2019

Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

October 31, 2019

Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

October 28, 2019

Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting

October 17, 2019

Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call

September 18, 2019

Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

August 28, 2019

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 13, 2019

Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment

August 13, 2019

Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

August 8, 2019

Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering

August 6, 2019

Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes

July 30, 2019

Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

July 18, 2019

Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call

June 18, 2019

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 13, 2019

Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

Copyright © 2022, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.